<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04102007</url>
  </required_header>
  <id_info>
    <org_study_id>M19-164</org_study_id>
    <secondary_id>2019-000904-14</secondary_id>
    <nct_id>NCT04102007</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab</brief_title>
  <official_title>A Phase 3b, Multicenter, Interventional, Open-label Study of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Have a Suboptimal Response to Secukinumab or Ixekizumab and Are Switched to Risankizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate whether adult participants with moderate to severe plaque psoriasis&#xD;
      who have been treated with secukinumab or ixekizumab for at least 6 months and are&#xD;
      experiencing a suboptimal response may benefit from switching to risankizumab with regard to&#xD;
      skin symptoms, quality of life symptoms and psoriasis symptoms.&#xD;
&#xD;
      Study duration will last for up to 64 weeks with risankizumab given by subcutaneous injection&#xD;
      at Week 0, Week 4, and then every 12 weeks for 52 Weeks. An additional visit will occur at&#xD;
      Week 8 for a physical exam and questionnaire collection. A final follow-up phone call will&#xD;
      occur at Week 60.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 12, 2019</start_date>
  <completion_date type="Anticipated">October 26, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 22, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Static Physician Global Assessment (sPGA) 0/1</measure>
    <time_frame>At Week 16</time_frame>
    <description>The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a sPGA Clear Response (sPGA 0)</measure>
    <time_frame>At Week 16</time_frame>
    <description>The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) 0 or 1</measure>
    <time_frame>At Week 16</time_frame>
    <description>The DLQI is a self-administered, ten-question questionnaire used to assess the effect of different skin diseases on a subject's quality of life, overall health, and disability status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Psoriasis Symptoms Scale (PSS) 0</measure>
    <time_frame>At Week 16</time_frame>
    <description>The PSS is a four-item patient-reported outcome instrument that assesses the severity of psoriasis symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving sPGA 0/1</measure>
    <time_frame>At Week 52</time_frame>
    <description>The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a sPGA 0</measure>
    <time_frame>At Week 52</time_frame>
    <description>The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a DLQI 0/1</measure>
    <time_frame>At Week 52</time_frame>
    <description>The DLQI is a self-administered, ten-question questionnaire used to assess the effect of different skin diseases on a subject's quality of life, overall health, and disability status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a PSS 0</measure>
    <time_frame>At Week 52</time_frame>
    <description>The PSS is a four-item patient-reported outcome instrument that assesses the severity of psoriasis symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve sPGA 0/1</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve sPGA 0</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Risankizumab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive Risankizumab following suboptimal response to secukinumab or ixekizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risankizumab</intervention_name>
    <description>Risankizumab is administered as a subcutaneous (SC) injection in pre-filled syringe (PFS).</description>
    <arm_group_label>Risankizumab</arm_group_label>
    <other_name>SKYRIZI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with moderate to severe chronic plaque psoriasis for at least 6 months&#xD;
             before Baseline (Week 0).&#xD;
&#xD;
          -  Participant must have been on labeled secukinumab or ixekizumab treatment for at least&#xD;
             6 months and are experiencing suboptimal response at time of Screening and Baseline&#xD;
             visits.&#xD;
&#xD;
          -  Participant must have a Body Surface Area (BSA) 3%- &lt;10% and Static Physician Global&#xD;
             Assessment (sPGA) 2/3&#xD;
&#xD;
          -  Participant must be eligible for continued biologic therapy as assessed by the&#xD;
             investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of erythrodermic psoriasis, generalized or localized pustular psoriasis,&#xD;
             medication-induced or medication-exacerbated psoriasis, or new onset guttate&#xD;
             psoriasis.&#xD;
&#xD;
          -  Participant with active skin disease other than plaque psoriasis that could interfere&#xD;
             with the assessment of plaque psoriasis.&#xD;
&#xD;
          -  History of any documented active or suspected malignancy or history of any malignancy&#xD;
             within the last 5 years except for successfully treated non-melanoma skin cancer&#xD;
             (NMSC) or localized carcinoma in situ of the cervix.&#xD;
&#xD;
          -  History of major surgery within 12 weeks prior to Baseline or planned to be performed&#xD;
             during the conduct of the trial as assessed by the investigator.&#xD;
&#xD;
          -  Participant with exposure to risankizumab or any IL-23 inhibitors.&#xD;
&#xD;
          -  No known active SARS-CoV-2 infection. -- At least 14 days since first PCR test result&#xD;
             have passed in asymptomatic participants or 14 days since recovery, defined as&#xD;
             resolution of fever without use of antipyretics and improvement in symptoms.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alliance Dermatology and MOHs /ID# 216001</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burke Pharmaceutical Research /ID# 225023</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913-6404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Research Trials /ID# 225497</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bakersfield Derma &amp; Skin Cance /ID# 213480</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Health /ID# 225367</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCD Research, PLLC /ID# 216062</name>
      <address>
        <city>Cromwell</city>
        <state>Connecticut</state>
        <zip>06416-1745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida International Rsrch cr /ID# 224983</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research /ID# 213484</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328-6141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Dermatology /ID# 216000</name>
      <address>
        <city>Rolling Meadows</city>
        <state>Illinois</state>
        <zip>60008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin, LLC /ID# 216004</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermAssociates /ID# 213837</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleaver Dermatology /ID# 226137</name>
      <address>
        <city>Kirksville</city>
        <state>Missouri</state>
        <zip>63501-5362</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Dermatology, PC /ID# 213479</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center /ID# 214795</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh MC /ID# 225644</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Partners, LLC /ID# 213836</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Research Center, Inc /ID# 215526</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellaire Dermatology /ID# 225486</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Modern Research Associates, PL /ID# 213835</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Menter Dermatology Res Inst /ID# 214002</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George Dermatology &amp; Skin Cancer Centre /ID# 213888</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veracity Clinical Research /ID# 213889</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Health Institute Inc /ID# 213886</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fremantle Dermatology /ID# 213887</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Erlangen /ID# 214228</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Frankfurt /ID# 215889</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 214469</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 215691</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ruhr Univ Bochum /ID# 225473</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologische Gemeinschaftspraxis Mahlow /ID# 225472</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beldio Research GmbH /ID# 225471</name>
      <address>
        <city>Memmingen</city>
        <zip>87700</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar - Technische Universitaet Muenchen /ID# 214506</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center /ID# 213815</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tel-Aviv</state>
        <zip>5239424</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center /ID# 213812</name>
      <address>
        <city>Tel Aviv-Yafo</city>
        <state>Tel-Aviv</state>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HaEmek Medical Center /ID# 214059</name>
      <address>
        <city>Afula</city>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center /ID# 213813</name>
      <address>
        <city>Petakh Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas /ID# 214749</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. di Bologna Policlinico S.Orsola-Malpighi /ID# 214745</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Cagliari- Presidio Ospedaliero /ID# 214748</name>
      <address>
        <city>Cagliari</city>
        <zip>09124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 214750</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Modena /ID# 214751</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Università degli Studi della Campania Luigi Vanvitelli /ID# 214752</name>
      <address>
        <city>Napoli</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol /ID# 214031</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Alcorcon /ID# 214033</name>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Parc de Salut del Mar /ID# 214034</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta del Mar /ID# 214428</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz /ID# 214341</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politecnico La Fe /ID# 214032</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital /ID# 213634</name>
      <address>
        <city>Taichung</city>
        <zip>40201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital /ID# 213630</name>
      <address>
        <city>Taipei City</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MacKay Memorial Hospital /ID# 213845</name>
      <address>
        <city>Taipei City</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Ho /ID# 213631</name>
      <address>
        <city>Taoyuan City</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victoria Hospital /ID# 213881</name>
      <address>
        <city>Kirkcaldy</city>
        <state>Fife</state>
        <zip>KY2 5AH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duplicate_Russells Hall Hospital, Dudley /ID# 213878</name>
      <address>
        <city>Dudley</city>
        <zip>DY1 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust /ID# 213880</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 213877</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Care Alliance NHS Group /ID# 213873</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>Related info</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 23, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plaque Psoriasis</keyword>
  <keyword>Risankizumab</keyword>
  <keyword>Secukinumab</keyword>
  <keyword>Ixekizumab</keyword>
  <keyword>Psoriasis</keyword>
  <keyword>Biologic</keyword>
  <keyword>Skyrizi</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

